메뉴 건너뛰기




Volumn 54, Issue 11, 2013, Pages 2458-2465

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): An Italian phase II trial of health-related quality of life, safety and efficacy

(20)  Oliva, Esther N a   Latagliata, Roberto b   Laganà, Carmelo a   Breccia, Massimo b   Galimberti, Sara c   Morabito, Fortunato d   Poloni, Antonella e   Balleari, Enrico f   Cortelezzi, Agostino g   Palumbo, Giuseppe h   Sanpaolo, Grazia i   Volpe, Antonio j   Specchia, Giorgina k   Finelli, Carlo l   D'Errigo, Maria Grazia a   Rodà, Filippo a   Alati, Caterina a   Alimena, Giuliana c   Nobile, Francesco a   Aloe Spiriti, Maria A m  


Author keywords

Del(5q); Health related quality of life; Lenalidomide; Myelodysplastic syndromes; Safety

Indexed keywords

HEMOGLOBIN; LENALIDOMIDE;

EID: 84880832214     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.778406     Document Type: Article
Times cited : (27)

References (21)
  • 1
    • 0037353935 scopus 로고    scopus 로고
    • A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life
    • Hellstrom-Lindberg E, Guibrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 2003;120: 1037-1046.
    • (2003) Br J Haematol , vol.120 , pp. 1037-1046
    • Hellstrom-Lindberg, E.1    Guibrandsen, N.2    Lindberg, G.3
  • 2
    • 53549108334 scopus 로고    scopus 로고
    • International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes
    • Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008;83:765-770.
    • (2008) Am J Hematol , vol.83 , pp. 765-770
    • Kao, J.M.1    McMillan, A.2    Greenberg, P.L.3
  • 3
    • 0036655766 scopus 로고    scopus 로고
    • Myelodysplastic syndrome overview
    • Kurzrock R. Myelodysplastic syndrome overview. Semin Hematol 2002;39(Suppl. 2):18-25.
    • (2002) Semin Hematol , vol.39 , Issue.SUPPL. 2 , pp. 18-25
    • Kurzrock, R.1
  • 4
    • 32144431895 scopus 로고    scopus 로고
    • Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making
    • Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005;23: 7594-7603.
    • (2005) J Clin Oncol , vol.23 , pp. 7594-7603
    • Malcovati, L.1    Porta, M.G.2    Pascutto, C.3
  • 5
    • 80053186861 scopus 로고    scopus 로고
    • Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic scoring system (WPSS)
    • Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011;96:1433-1440.
    • (2011) Haematologica , vol.96 , pp. 1433-1440
    • Malcovati, L.1    Della Porta, M.G.2    Strupp, C.3
  • 6
    • 30144443817 scopus 로고    scopus 로고
    • The myelodysplastic syndromes: Diagnosis and treatment
    • Steensma DP, Bennett TM. The myelodysplastic syndromes: Diagnosis and treatment. Mayo din Proc 2006;81:104-130.
    • (2006) Mayo Din Proc , vol.81 , pp. 104-130
    • Steensma, D.P.1    Bennett, T.M.2
  • 7
    • 0037541576 scopus 로고    scopus 로고
    • Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes
    • Jansen AJ, Essink-Bot ML, Beckers EA, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003;121:270-274.
    • (2003) Br J Haematol , vol.121 , pp. 270-274
    • Jansen, A.J.1    Essink-Bot, M.L.2    Beckers, E.A.3
  • 8
    • 70349502130 scopus 로고    scopus 로고
    • Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review
    • Pinchon DJ, Stanworth SJ, Dorée C, et al. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol 2009;84:671-677.
    • (2009) Am J Hematol , vol.84 , pp. 671-677
    • Pinchon, D.J.1    Stanworth, S.J.2    Dorée, C.3
  • 9
    • 0037099753 scopus 로고    scopus 로고
    • More concern about transfusion requirement when evaluating quality of life in anemic patients
    • Oliva EN, D?Angelo A, Martino B, et al. More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol 2002;20:3182-3183.
    • (2002) J Clin Oncol , vol.20 , pp. 3182-3183
    • Oliva, E.N.1    Dangelo, A.2    Martino, B.3
  • 10
    • 84855965633 scopus 로고    scopus 로고
    • A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes
    • Oliva EN, Schey C, Hutchings AS. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. Am J Blood Res 2011;1:160-166.
    • (2011) Am J Blood Res , vol.1 , pp. 160-166
    • Oliva, E.N.1    Schey, C.2    Hutchings, A.S.3
  • 11
    • 84858748853 scopus 로고    scopus 로고
    • The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes
    • Platzbecker U, Hofbauer LC, Ehninger G, et al. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res 2012;36:525-536.
    • (2012) Leuk Res , vol.36 , pp. 525-536
    • Platzbecker, U.1    Hofbauer, L.C.2    Ehninger, G.3
  • 12
    • 77953425222 scopus 로고    scopus 로고
    • Efficace e Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes
    • Caocci G, La Nasa G, Efficace E Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. Expert Rev Hematol 2009;2:69-80.
    • (2009) Expert Rev Hematol , vol.2 , pp. 69-80
    • Caocci, G.1    La Nasa, G.2
  • 13
    • 0035366382 scopus 로고    scopus 로고
    • Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to threetimes-weekly dosing
    • Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to threetimes-weekly dosing. J Clin Oncol 2001;19:2875-2882.
    • (2001) J Clin Oncol , vol.19 , pp. 2875-2882
    • Gabrilove, J.L.1    Cleeland, C.S.2    Livingston, R.B.3
  • 14
    • 33749438404 scopus 로고    scopus 로고
    • Lenalidomide in the myelodysplastic syndrome with chromosome Sq deletion
    • List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome Sq deletion. N Engl Med 2006;355:1456-1465.
    • (2006) N Engl Med , vol.355 , pp. 1456-1465
    • List, A.1    Dewald, G.2    Bennett, J.3
  • 15
    • 80053621748 scopus 로고    scopus 로고
    • A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-I-risk myelodysplastic syndromes with delSq
    • Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-I-risk myelodysplastic syndromes with delSq. Blood 2011;118:3765-3776.
    • (2011) Blood , vol.118 , pp. 3765-3776
    • Fenaux, P.1    Giagounidis, A.2    Selleslag, D.3
  • 16
    • 33745968917 scopus 로고    scopus 로고
    • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108:419-425.
    • (2006) Blood , vol.108 , pp. 419-425
    • Cheson, B.D.1    Greenberg, P.L.2    Bennett, J.M.3
  • 17
    • 23844489776 scopus 로고    scopus 로고
    • Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome
    • Oliva EN, Dimitrov BD, Benedetto F, et al. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. LeukRes 2005;29:1217-1219.
    • (2005) Leuk Res , vol.29 , pp. 1217-1219
    • Oliva, E.N.1    Dimitrov, B.D.2    Benedetto, F.3
  • 18
    • 84856487158 scopus 로고    scopus 로고
    • Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with Sq deletion. A comparative analysis by the groupe Francophone des Myelodysplasies
    • Adès L, Le Bras F, Sebert M, et al. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with Sq deletion. A comparative analysis by the groupe Francophone des Myelodysplasies. Haematologica 2012;97:213-218.
    • (2012) Haematologica , vol.97 , pp. 213-218
    • Adès, L.1    Le Bras, F.2    Sebert, M.3
  • 19
    • 84885673761 scopus 로고    scopus 로고
    • Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low-or Intermediate-I-risk MDS with del(Sq): A comparative analysis
    • 2012 Dec 21[Epub ahead of print]
    • Kuendgen A, Lauseker M, List AF, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low-or Intermediate-I-risk MDS with del(Sq): A comparative analysis. Leukemia 2012 Dec 21. [Epub ahead of print]
    • Leukemia
    • Kuendgen, A.1    Lauseker, M.2    List, A.F.3
  • 20
    • 84885675989 scopus 로고    scopus 로고
    • Treatment with lenalidomide in myelodysplastic syndromes with deletion Sq: Results from the Dutch named patient program
    • 2012 Sep 28[Epub ahead of print]
    • Abouyahya I, Alhan C, Westers TM, et al. Treatment with lenalidomide in myelodysplastic syndromes with deletion Sq: Results from the Dutch named patient program. Leuk Lymphoma 2012 Sep 28. [Epub ahead of print]
    • Leuk Lymphoma
    • Abouyahya, I.1    Alhan, C.2    Westers, T.M.3
  • 21
    • 84860744403 scopus 로고    scopus 로고
    • Continuous lenalidomide treatment for newly diagnosed multiple myeloma
    • Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-1769.
    • (2012) N Engl J Med , vol.366 , pp. 1759-1769
    • Palumbo, A.1    Hajek, R.2    Delforge, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.